Sandoz Group Ag Stock Earnings Reports

Sandoz delivered a strong 2025 with net sales of $11.1bn (up 5% cc), core EBITDA margin of 21.7% (up 160bps) and management free cash flow of $1.5bn. Biosimilars are a major growth driver—representing ~30% of sales (31% in Q4) and growing double-digits—supported by multiple successful launches (Pyzchiva, Wyost/Jubbonti, Tyruko, Afqlir) and a deep pipeline (27 biosimilars and >400 generic assets). The company closed the Just‑Evotec Biologics Europe acquisition to strengthen biologics tech and is building an end‑to‑end European biosimilars hub in Slovenia. Financially, ROIC improved to 14.5%, core diluted EPS rose 33%, net debt (reported) was $3.6bn (underlying net debt down to $3.1bn), and CapEx was ~$700m in 2025 with guidance of ~ $1.1bn for 2026 (peak year, primarily for biosimilars). 2026 guidance: mid‑ to high‑single‑digit net sales growth (cc), ~100bps core EBITDA margin expansion, low‑ to mid‑single‑digit price erosion; currency expected to add ~2pp to sales. Key near‑term headwinds/risks include continued adverse dynamics in the penicillin B2B business (price dumping from Asian suppliers affecting H1 2026), some one‑off integration/IT costs, ongoing patent/IP and regulatory uncertainty in certain markets (notably the U.S.), and FX volatility. Management emphasizes continued disciplined SG&A control, higher R&D investment to support the pipeline, manufacturing cost savings potential, and a multi‑year opportunity from LOEs (large LOE pools for both biologics and generics).